Ignite Creation Date:
2025-12-24 @ 12:46 PM
Ignite Modification Date:
2025-12-27 @ 9:31 PM
Study NCT ID:
NCT00085761
Status:
TERMINATED
Last Update Posted:
2008-03-06
First Post:
2004-06-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
Sponsor:
NeurogesX
Organization:
Study Overview
Official Title:
An International, Multicenter, Randomized, Double-Blind, 12-Week Controlled Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
Status:
TERMINATED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated in view of the C107 findings demonstrating efficacy at doses of 90 and 30 minutes
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful HIV-associated neuropathy.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: